Ftse Mib
33.887,05
0,62%
DAX
18.996,63
0,89%
S&P 500
5.726,44
0,14%
NASDAQ
18.071,60
0,54%
Bitcoin
63.606,65
0,44%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Precigen Inc (PGEN) Precigen Inc (PGEN) Notizie

PGEN

Precigen (PGEN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PGEN
DataOraFonteTitoloSimboloCompagnia
16/09/202422:30PR Newswire (US)Precigen to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:PGENPrecigen Inc
30/08/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PGENPrecigen Inc
14/08/202422:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PGENPrecigen Inc
14/08/202422:05PR Newswire (US)Precigen Reports Second Quarter and First Half 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
13/08/202423:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
09/08/202414:00PR Newswire (US)Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14thNASDAQ:PGENPrecigen Inc
08/08/202422:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:PGENPrecigen Inc
08/08/202403:30PR Newswire (US)Precigen Announces Pricing of $30.0 Million Public Offering of Common StockNASDAQ:PGENPrecigen Inc
06/08/202422:04PR Newswire (US)Precigen Announces Proposed $30 Million Public Offering of Common StockNASDAQ:PGENPrecigen Inc
06/08/202422:01PR Newswire (US)Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy LaunchNASDAQ:PGENPrecigen Inc
24/07/202423:20Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PGENPrecigen Inc
23/07/202414:01PR Newswire (US)Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy LaunchNASDAQ:PGENPrecigen Inc
03/06/202415:30PR Newswire (US)Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete ResponseNASDAQ:PGENPrecigen Inc
28/05/202422:48Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:PGENPrecigen Inc
28/05/202422:44Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PGENPrecigen Inc
23/05/202423:00PR Newswire (US)Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
14/05/202422:05PR Newswire (US)Precigen Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
08/05/202422:05PR Newswire (US)Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202416:20PR Newswire (US)Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual MeetingNASDAQ:PGENPrecigen Inc
24/04/202415:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:PGENPrecigen Inc
28/03/202421:05PR Newswire (US)Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11thNASDAQ:PGENPrecigen Inc
19/03/202421:05PR Newswire (US)Precigen Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:PGENPrecigen Inc
19/03/202412:27IH Market NewsUS Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices RetreatNASDAQ:PGENPrecigen Inc
12/03/202421:05PR Newswire (US)Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory PapillomatosisNASDAQ:PGENPrecigen Inc
05/03/202422:05PR Newswire (US)Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19thNASDAQ:PGENPrecigen Inc
27/02/202419:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PGENPrecigen Inc
14/02/202422:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PGENPrecigen Inc
06/02/202422:05PR Newswire (US)Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:PGENPrecigen Inc
18/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PGENPrecigen Inc
16/01/202414:05PR Newswire (US)Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European CommissionNASDAQ:PGENPrecigen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PGEN

La tua Cronologia

ASX
AQMHA
Anglo American Capital
LSE
QO38
Morg.st.b.v 24
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network